论文部分内容阅读
目的观察奥沙利铂(OXA)联合替吉奥(S-1)治疗晚期胃癌的疗效和不良反应。方法 37例经紫杉类药物治疗失败后晚期胃癌患者,应用OXA联合S-1:OXA,130mg/m2,静脉滴注,第1天;S-1根据体表面积(BSA)按80、100和120mg/d给药,分2次口服,第1-14天;持续至疾病进展或出现不可耐受的不良反应。每2个周期按照RECIST标准(1.1版)进行疗效评价,按NCI-CTC(4.0版)评价不良反应并随访生存情况。结果在37例可评价的患者中获得完全缓解2例,部分缓解9例;疾病稳定11例,疾病进展15例,有效率29.7%,总的疾病控制率为59.5%。中位疾病进展时间为3.7个月,中位生长期为7.6个月,主要不良反应为骨髓抑制、肝功能受损和消化道反应。结论 OXA联合S-1二线治疗晚期胃癌有一定疗效,不良反应可以耐受,值得深入观察。
Objective To observe the efficacy and side effects of oxaliplatin (OXA) combined with tegaserod (S-1) in the treatment of advanced gastric cancer. Methods Thirty-seven patients with advanced gastric cancer who had failed treatment with taxanes were treated with intravenous infusion of OXA combined with S-1: OXA (130 mg / m2) on day 1; S-1 120mg / d administration, 2 times orally, 1-14 days; continued to disease progression or intolerable adverse reactions. The curative effect was evaluated according to RECIST standard (version 1.1) every 2 cycles. The adverse reactions were evaluated according to NCI-CTC (version 4.0) and the survival was followed up. Results In 37 evaluable patients, complete remission was achieved in 2 cases and partial remission in 9 cases. The disease was stable in 11 cases, the disease progressed in 15 cases, the effective rate was 29.7% and the total disease control rate was 59.5%. The median time to progression was 3.7 months, with a median duration of 7.6 months. The major adverse effects were myelosuppression, impaired liver function, and digestive tract response. Conclusion OXA combined with S-1 second-line treatment of advanced gastric cancer have a certain effect, adverse reactions can tolerate, it is worth in-depth observation.